<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777736</url>
  </required_header>
  <id_info>
    <org_study_id>CLSG-CNS-001</org_study_id>
    <secondary_id>2015-000591-97</secondary_id>
    <nct_id>NCT02777736</nct_id>
  </id_info>
  <brief_title>CNS Prophylaxis in Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>CLSG-CNS-001</acronym>
  <official_title>Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Czech Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Czech Lymphoma Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of cumulative incidence of CNS relapses in patients with diffuse large B-cell
      lymphoma with intermediate or high risk of CNS relapse treated with CNS prophylaxis: either
      with 2 doses of intravenous methotrexate 3g/m2 i.v.(arm A) or 6 doses of intrathecal
      methotrexate 12mg (arm B) and in patients with low risk of CNS relapse without CNS
      prophylaxis (arm C).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diffuse large B-cell lymphoma are evaluated for risk factors of CNS relapse
      during initial staging (age &gt; 60years, lactate dehydrogenase (LDH) &gt; reference range,
      clinical stage III/IV, performance status according to Eastern Cooperative Oncology Group
      (ECOG) &gt;1, kidney and/or adrenal gland involvement, involvement &gt; 1 extranodal organ)
      including evaluation of cerebrospinal fluid.

      All patients with systemic DLBCL without CNS involvement are treated with systemic
      chemotherapy: either 6 cycles of R CHOP (rituximab, cyclophosphamide, doxorubicin,
      vincristine, prednison) +2xR (rituximab) or 6 cycles of DA EPOCH R (dose adjusted etoposide,
      prednison, vincristin, cyclophosphamide, doxorubicin) +2xR (rituximab). Patients with ≥ 2
      risk factors for CNS relapse or with occult meningeal involvement will be randomized in 1:1
      ratio either into arm A with 2 cycles of prophylactic methotrexate 3g/m2 i.v., or into arm B
      with prophylactic 6x intrathecal methotrexate 12mg (1x intrathecal methotrexate in each cycle
      of systemic chemotherapy). Patients with 0-1 risk factor will be allocated into arm C without
      CNS prophylaxis. Patients will be observed for CNS relapse during the follow-up of 1year
      after the end of the first-line treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of CNS relapse in patients treated either with methotrexate i.v. or methotrexate i.t. or without CNS prophylaxis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A - Methotrexate i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Methotrexate i.t.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - no Methotrexate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>i.v. or intrathecal CNS prophylaxis</description>
    <arm_group_label>Arm A - Methotrexate i.v.</arm_group_label>
    <arm_group_label>Arm B - Methotrexate i.t.</arm_group_label>
    <other_name>Methotrexate,manufactured by EBEWE</other_name>
    <other_name>Methotrexate, manufactured by HOSPIRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed DLBCL

          -  age 18-72 years

          -  signed informed consent with the study

          -  first-line treatment 6 cycles of R CHOP +2x R or 6 cycles of DA EPOCH R+ 2xR

        Exclusion Criteria:

          -  DLBCL and concomitant initial CNS involvement

          -  PMBL (primary mediastinal B-cell lymphoma)

          -  treatment with another chemotherapy than R CHOP or DA EPOCH R

          -  HIV positive, or active hepatitis B or C

          -  other concomitant serious disease (based on the decision of the
             physician-investigator)

          -  non-compliance of a patient

          -  any contraindication for application of anthracycline based chemotherapy or high dose
             methotrexate

          -  pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi Mocikova, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Kralovske Vinohrady, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Trněný, prof.M.D.</last_name>
    <role>Study Director</role>
    <affiliation>General University Hospital, Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Mocikova, M.D., Ph.D.</last_name>
    <phone>+420267163554</phone>
    <email>heidi.mocikova@fnkv.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Brno-Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Janikova, M.D.,Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Belada, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juraj Ďuraš, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Pilsen</name>
      <address>
        <city>Pilsen</city>
        <zip>304 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Pachner, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Mocikova, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Pytlik, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.lymphoma.cz</url>
    <description>Official Site of the Czech Lymphoma Study Group</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma, B cell</keyword>
  <keyword>Central nervous system relapse</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Intrathecal chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

